Condition: Advanced Solid Tumor · Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
To evaluate the efficacy and safety of SPH7485 tablets in patients with advanced solid tumors.
This description comes directly from the study's public registry record.
Xiaohua Wu · 0086-021-34778299 · shanboer@126.com
Jian Zhang
Always discuss trial participation with your own doctor first.
| XiangYa Hospital CentralSouth University | Changsha, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, China | Recruiting |
| Yunnan Cancer Hospital | Kunming, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06487455